S&P 500   4,264.78 (+1.37%)
DOW   33,677.68 (+1.02%)
QQQ   329.26 (+1.60%)
AAPL   171.36 (+1.70%)
MSFT   290.15 (+1.09%)
META   179.67 (+1.23%)
GOOGL   120.84 (+1.68%)
AMZN   141.92 (+0.91%)
TSLA   892.29 (+3.77%)
NVDA   185.63 (+3.46%)
NIO   21.07 (+1.20%)
BABA   94.50 (-0.39%)
AMD   100.72 (+2.65%)
MU   64.98 (+4.27%)
T   18.18 (+0.78%)
CGC   3.29 (+4.44%)
GE   79.30 (+0.51%)
F   16.15 (+2.02%)
DIS   120.58 (+2.46%)
AMC   24.84 (-2.44%)
PYPL   100.99 (+1.90%)
PFE   50.03 (+3.60%)
NFLX   247.84 (+2.12%)
S&P 500   4,264.78 (+1.37%)
DOW   33,677.68 (+1.02%)
QQQ   329.26 (+1.60%)
AAPL   171.36 (+1.70%)
MSFT   290.15 (+1.09%)
META   179.67 (+1.23%)
GOOGL   120.84 (+1.68%)
AMZN   141.92 (+0.91%)
TSLA   892.29 (+3.77%)
NVDA   185.63 (+3.46%)
NIO   21.07 (+1.20%)
BABA   94.50 (-0.39%)
AMD   100.72 (+2.65%)
MU   64.98 (+4.27%)
T   18.18 (+0.78%)
CGC   3.29 (+4.44%)
GE   79.30 (+0.51%)
F   16.15 (+2.02%)
DIS   120.58 (+2.46%)
AMC   24.84 (-2.44%)
PYPL   100.99 (+1.90%)
PFE   50.03 (+3.60%)
NFLX   247.84 (+2.12%)
S&P 500   4,264.78 (+1.37%)
DOW   33,677.68 (+1.02%)
QQQ   329.26 (+1.60%)
AAPL   171.36 (+1.70%)
MSFT   290.15 (+1.09%)
META   179.67 (+1.23%)
GOOGL   120.84 (+1.68%)
AMZN   141.92 (+0.91%)
TSLA   892.29 (+3.77%)
NVDA   185.63 (+3.46%)
NIO   21.07 (+1.20%)
BABA   94.50 (-0.39%)
AMD   100.72 (+2.65%)
MU   64.98 (+4.27%)
T   18.18 (+0.78%)
CGC   3.29 (+4.44%)
GE   79.30 (+0.51%)
F   16.15 (+2.02%)
DIS   120.58 (+2.46%)
AMC   24.84 (-2.44%)
PYPL   100.99 (+1.90%)
PFE   50.03 (+3.60%)
NFLX   247.84 (+2.12%)
S&P 500   4,264.78 (+1.37%)
DOW   33,677.68 (+1.02%)
QQQ   329.26 (+1.60%)
AAPL   171.36 (+1.70%)
MSFT   290.15 (+1.09%)
META   179.67 (+1.23%)
GOOGL   120.84 (+1.68%)
AMZN   141.92 (+0.91%)
TSLA   892.29 (+3.77%)
NVDA   185.63 (+3.46%)
NIO   21.07 (+1.20%)
BABA   94.50 (-0.39%)
AMD   100.72 (+2.65%)
MU   64.98 (+4.27%)
T   18.18 (+0.78%)
CGC   3.29 (+4.44%)
GE   79.30 (+0.51%)
F   16.15 (+2.02%)
DIS   120.58 (+2.46%)
AMC   24.84 (-2.44%)
PYPL   100.99 (+1.90%)
PFE   50.03 (+3.60%)
NFLX   247.84 (+2.12%)
NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$42.96
+0.60 (+1.42%)
(As of 08/12/2022 02:33 PM ET)
Add
Compare
Today's Range
$42.12
$43.12
50-Day Range
$35.61
$49.49
52-Week Range
$35.34
$108.99
Volume
36,821 shs
Average Volume
1.95 million shs
Market Capitalization
$7.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.00

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
66.3% Upside
$71.00 Price Target
Short Interest
Healthy
5.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.17mentions of Exact Sciences in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$251,872 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.21) to ($3.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

62nd out of 1,117 stocks

Medical Laboratories Industry

1st out of 28 stocks

EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Price Performance

Exact Sciences stock traded up $0.54 during mid-day trading on Friday, reaching $42.90. The company had a trading volume of 31,919 shares, compared to its average volume of 1,954,481. The stock's 50-day simple moving average is $44.06 and its 200-day simple moving average is $58.14. The company has a market capitalization of $7.59 billion, a P/E ratio of -10.01 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.48 and a quick ratio of 2.23. Exact Sciences has a 1 year low of $35.34 and a 1 year high of $108.99.

Analyst Upgrades and Downgrades

EXAS has been the subject of a number of recent analyst reports. StockNews.com raised Exact Sciences from a "sell" rating to a "hold" rating in a report on Tuesday, July 26th. Citigroup cut their price objective on shares of Exact Sciences from $65.00 to $50.00 and set a "neutral" rating on the stock in a report on Wednesday, August 3rd. Cowen lowered their target price on shares of Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a report on Wednesday, August 3rd. Robert W. Baird cut their price target on shares of Exact Sciences from $90.00 to $75.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 3rd. Finally, Cowen dropped their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average target price of $71.00.

Insider Activity

In other Exact Sciences news, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at $2,420,561.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Exact Sciences news, Director Katherine S. Zanotti sold 1,086 shares of the stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the sale, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Katherine S. Zanotti sold 4,608 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company's stock, valued at $2,722,754.52. The disclosure for this sale can be found here. Insiders sold a total of 5,701 shares of company stock worth $251,872 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

Exact Sciences (NASDAQ:EXAS) PT Raised to $65.00 at Evercore ISI
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
Exact Sciences (EXAS) Q2 2022 Earnings Call Transcript
Top 10 Stock Picks of Eli Casdin’s Casdin Capital
EXAS December 16th Options Begin Trading
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
11/01/2021
Today
8/12/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$71.00
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+65.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-595,630,000.00
Pretax Margin
-38.51%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$18.14 per share

Miscellaneous

Free Float
174,660,000
Market Cap
$7.60 billion
Optionable
Optionable
Beta
1.32

Social Links















EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2022?

11 brokers have issued 1 year price targets for Exact Sciences' stock. Their EXAS share price forecasts range from $50.00 to $130.00. On average, they expect the company's stock price to reach $71.00 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2022?

Exact Sciences' stock was trading at $77.83 at the start of the year. Since then, EXAS shares have decreased by 45.1% and is now trading at $42.69.
View the best growth stocks for 2022 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Monday, November, 1st. The medical research company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.08. The medical research company earned $456.38 million during the quarter, compared to analyst estimates of $429.04 million. Exact Sciences had a negative trailing twelve-month return on equity of 22.07% and a negative net margin of 37.90%. During the same period in the previous year, the business earned ($0.36) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.98 billion-$2.02 billion, compared to the consensus revenue estimate of $2.02 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (8.51%), Sumitomo Mitsui Trust Holdings Inc. (3.30%), Nikko Asset Management Americas Inc. (3.02%), Baillie Gifford & Co. (2.49%), Artisan Partners Limited Partnership (0.60%) and Swiss National Bank (0.43%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $42.69.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $7.55 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.